US FDA’s Marks Worries Someone May Stop Hybrid Work System

Patrizia Cavazzoni and Peter Marks continue to trumpet the benefits of the US Food and Drug Administration’s hybrid workplace, but a concern lingers that the momentum could lost.

Since the FDA moved to a system allowing most employees to work from home or the office at the beginning of the year, Marks, director of the FDA’s Center for Biologics Evaluation and Research, and Cavazzoni, director of the Center for Drug Evaluation and Research, have largely praised the results